About Us

We were founded in 2019 and made our first investment into a small biotech company, CytoDyn Inc. Our collective holdings of CytoDyn Inc. have reached a market value in excess of one hundred million dollars in recent weeks. We have primarily acquired preferred stock of CytoDyn Inc. Our acquisitions include Series C and Series D preferred stock in CytoDyn Inc. Our holdings in preferred stock of the company are most notable for some of the unique preference features of both Series C and Series D Preferred Stock. While these preference characteristics are somewhat challenging to understand and quantify, we believe the complication to be well worth the effort. If and when CytoDyn Inc. is successful and prosperous, the preference characteristics will be greatly enjoyed by our group of investors.

News Feeds CytoDyn

Source: CytoDyn Inc.

Contact Us